Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Precancerous Conditions 1Neoplasms 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 4Imiquimod 3VGX-3100 2Conization 2Colposcopy 2Blood Specimen Collection 2lime 1hecolin 1Vaginal Smears 1Vaccines, Synthetic 1Spectrometry, Fluorescence 1Polymerase Chain Reaction 1Papillomavirus Vaccines 1Olive Oil 1Mass Screening 1Isotretinoin 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Hepatitis A Vaccines 1Fluorouracil 1Fenretinide 1Electroporation 1Cryosurgery 1AKAP13 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uterine Cervical Dysplasia × Fenretinide × Clear all
NCT00003075 2018-10-24

Fenretinide in Treating Patients With Cervical Neoplasia

M.D. Anderson Cancer Center

Phase 3 Completed
39 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡